-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Hypoxia-Inducible Factor Activators: A Novel Class of Oral Drugs for the Treatment of Anemia of Chronic Kidney Disease

Program: Education Program
Session: Integrating New Therapies into the Management of Classical Heme Disorders
Hematology Disease Topics & Pathways:
Adult, Drug-drug interactions, Education, Hematopoiesis, Diseases, Treatment Considerations, Non-Biological therapies, Adverse Events, Pharmacology, Biological Processes, Molecular biology, Study Population, Human, Pathogenesis
Saturday, December 7, 2024, 2:00 PM-3:15 PM

Volker Hans Haase, MD

Medicine, Vanderbilt University, Nashville, TN; Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University, Nashville, TN

Disclosures: Haase: Akebia Therapeutics: Honoraria; GlaxoSmithKline: Honoraria.

See more of: Integrating New Therapies into the Management of Classical Heme Disorders
See more of: Education Program
Previous Presentation | Next Presentation >>